Ignite Creation Date:
2024-05-06 @ 6:01 PM
Last Modification Date:
2024-10-26 @ 2:39 PM
Study NCT ID:
NCT05510089
Status:
RECRUITING
Last Update Posted:
2023-10-10
First Post:
2022-08-18
Brief Title:
EtoposideCytarabinePEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
Sponsor:
The Affiliated Peoples Hospital of Ningbo University
Organization:
The Affiliated Peoples Hospital of Ningbo University
Study Overview
Official Title:
Prospective Single-arm Multicenter Exploratory Clinical Study of the Combination of Etoposide Cytarabine and PEG-rhG-CSF EAP Regimen on Hematopoietic Stem Cell Mobilization in Poor Mobilization Patients With Hematological Malignancies
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm multicenter exploratory clinical study to evaluate the safety and efficacy of the combination of etoposide cytarabine and PEG-rhG-CSF EAP regimen on hematopoietic stem cell mobilization in poor mobilization patients with hematological malignancies All eligible patients will receive EAP regimen treatment then the number of CD34 cells and white blood cells will be monitoring When the collection standard is met hematopoietic stem cell collection will be started
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None